Details of the Drug

General Information of Drug (ID: DMS7OU8)

• Drug Name: Elapegademase
• Synonyms: Elapegademase [INN]; UNII-9R3D3Y0UHS; Elapegademase [USAN:INN]; 9R3D3Y0UHS

Indication

Disease Entry	ICD 11	Status	REF
Adenosine deaminase defciency	4A01.1	Approved	[1]
Immunodeficiency	4A00-4A85	Phase 3	[2]

• Sequence:
  AQTPAFNKPKVELHVHLDGAIKPETILYYGRKRGIALPADTPEELQNIIGMDKPLSLPEF
  LAKFDYYMPAIAGSREAVKRIAYEFVEMKAKDGVVYVEVRYSPHLLANSKVEPIPWNQAE
  GDLTPDEVVSLVNQGLQEGERDFGVKVRSILCCMRHQPSWSSEVVELCKKYREQTVVAID
  LAGDETIEGSSLFPGHVKAYAEAVKSGVHRTVHAGEVGSANVVKEAVDTLKTERLGHGYH
  TLEDTTLYNRLRQENMHFEVCPWSSYLTGAWKPDTEHPVVRFKNDQVNYSLNTDDPLIFK
  STLDTDYQMTKNEMGFTEEEFKRLNINAAKSSFLPEDEKKELLDLLYKAYGMPSPA
• ADMET Property:
  Absorption AUC: The area under the plot of plasma concentration (AUC) of drug is 33000000 micromolh/L []
  Absorption Tmax: The time to maximum plasma concentration (Tmax) is 60 h []
  Metabolism: The drug is metabolized via proteases to small peptides and individual amino acids []
• Cross-matching ID:
  PubChem CID: 121488177
  DrugBank ID: DB14712
  TTD ID: D01VEJ
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adenosine deaminase (ADA)	TTLP57V	ADA_HUMAN	Modulator	[1]

References

• [1] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [2] ClinicalTrials.gov (NCT01420627) EZN-2279 in Patients With ADA-SCID. U.S. National Institutes of Health.